District One Hospital

Running trials

• Recruiting

  Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

  NCT07410494· Phase 1/2· Source

• Recruiting

  EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

  NCT07410676· Phase 1/2· Source

• Recruiting

  Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas

  NCT07066982· Phase 1/2· Source

• Recruiting

  Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma

  NCT07032129· Phase 1/2· Source

• Recruiting

  Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer

  NCT07066995· Phase 1/2· Source

• Recruiting

  Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer

  NCT07067255· Phase 1/2· Source

• Recruiting

  TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas

  NCT06640582· Phase 1/2· Source

• Recruiting

  Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer

  NCT06530303· Phase 1/2· Source

• Recruiting

  TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer

  NCT06532799· Phase 1/2· Source

• Recruiting

  TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer

  NCT06532812· Phase 1/2· Source

• Recruiting

  TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer

  NCT06538012· Phase 1/2· Source

• Recruiting

  Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease

  NCT06399107· Phase 1/2· Source

• Recruiting

  Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells

  NCT06420076· Phase 1/2· Source

• Recruiting

  Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

  NCT06213636· Phase 1/2· Source

• Recruiting

  Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML

  NCT06420063· Phase 1/2· Source

• Recruiting

  Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases

  NCT06428188· Phase 1/2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers10 recruiting
• Lung cancer4 recruiting
• Colorectal cancer3 recruiting
• Glioblastoma3 recruiting
• Ovarian cancer3 recruiting
• Pancreatic cancer3 recruiting
• Sarcoma3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Acute myeloid leukemia2 recruiting
• Follicular lymphoma2 recruiting
• Gastric and esophageal cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Melanoma2 recruiting
• Multiple myeloma2 recruiting
• Prostate cancer2 recruiting
• Bladder cancer1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Kidney cancer1 recruiting
• Lupus (SLE)1 recruiting
• Metastatic breast cancer1 recruiting
• Sickle cell disease1 recruiting
• Sjögren's disease1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.